Clinical focus and interest:
Dr. Kao has a wide clinical, translational, and psychosocial research interest in thoracic cancers, with a special interest in managing treatment-resistant thoracic cancers using new treatments such as immunotherapy and targeted therapies.
Dr. Kao completed his PhD on predictive and prognostic factors in malignant mesothelioma in 2013. He was the chief investigator in several trials for which he received research grants and has authored more than 35 original peer-reviewed publications. Dr. Kao has received multiple awards, including the Excellence in Translational Cancer Research award as a member of a team investigating mesothelioma in 2014 and the Outstanding Cancer Research Scholar award in 2012, which were both from the Cancer Institute NSW Premier’s Awards for Outstanding Cancer Research program.